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Intestinal Inflammation Modulates the Epithelial Response to 
Butyrate in Patients With Inflammatory Bowel Disease
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Background: Butyrate-producing gut bacteria are reduced in patients with active inflammatory bowel disease (IBD), supporting the hypothesis 
that butyrate supplementation may be beneficial in this setting. Nonetheless, earlier studies suggest that the oxidation of butyrate in IBD patients 
is altered. We propose that inflammation may decrease epithelial butyrate consumption.
Methods: Non-IBD controls and IBD patients were recruited for the study. Stool samples were used for short-chain fatty acid and bacterial 
butyryl CoA:acetate CoA-transferase quantification. Colonic biopsies and ex vivo differentiated epithelial organoids (d-EpOCs) treated with bu-
tyrate and/or tumor necrosis factor alpha (TNFα) were used for analyzing the expression of transporters MCT1 and ABCG2, metabolic enzyme 
ACADS, and butyrate receptor GPR43, and for butyrate metabolism and consumption assays.
Results: We observed that lower stool content of butyrate-producing bacteria in active IBD patients did not correlate with decreased bu-
tyrate concentrations. Indeed, the intestinal epithelial expression of MCT1, ABCG2, ACADS, and GPR43 was altered in active IBD patients. 
Nonetheless, d-EpOCs derived from IBD patients showed SLC16A1 (gene encoding for MCT1 protein), ABCG2, ACADS, and GPR43 expres-
sion levels comparable to controls. Moreover, IBD- and non-IBD-derived d-EpOCs responded similarly to butyrate, as assessed by transcriptional 
regulation. TNFα significantly altered SLC16A1, ABCG2, and GPR43 transcription in d-EpOCs, mimicking the expression profile observed in 
biopsies from active IBD patients and resulting in reduced butyrate consumption.
Conclusions: We provide evidence that the response to butyrate is not intrinsically altered in IBD patients. However, TNFα renders the epithe-
lium less responsive to this metabolite, defeating the purpose of butyrate supplementation during active inflammation.
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INTRODUCTION
Crohn’s disease (CD) and ulcerative colitis (UC) are 
considered the 2 major forms of chronic inflammatory bowel 
diseases (IBDs). Although their etiology is still poorly under-
stood, growing evidence supports a role for defects within the 
epithelial cell compartment in driving disease.1–3 The intes-
tinal epithelium is a single layer of specialized cells covering 
the mucosal surface that are organized into thousands of 
invaginations called crypts. At the base of each crypt, a small 
number of multipotent adult stem cells differentiate into the 
distinct epithelial lineages.4 The epithelial layer is crucial in 
maintaining intestinal homeostasis by interacting with both 
commensal and pathogenic bacteria, and with the underlying 
immune cells.
Gut microbial dysbiosis in IBD is a well-established obser-
vation.5 Indeed, several groups have reported important changes 
in the fecal and mucosa-associated microbial communities in 
different patient cohorts.6, 7 One commonly reported altera-
tion associated with IBD is a decrease in short-chain fatty acid 
(SCFA)–producing bacteria, in particular butyrate-synthesizing 
species such as Roseburia and Faecalibacterium prausnitzii.8, 9 In 
agreement with this, other studies have noted a reduced capacity 
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for butyrate synthesis based on stool samples taken from IBD 
patients. This was established by measuring the expression of 
Butyril-CoA:acetate CoA-transferase (BCoAT), 1 of the bacte-
rial enzymes responsible for butyrate synthesis.8, 9 Alterations in 
stool SCFA concentrations have also been observed.10–12 In ad-
dition to changes in butyrate production, previous studies have 
also suggested potential alterations in butyrate oxidation in IBD 
patients,13 which could impair the ability of butyrate to exert 
its potentially beneficial effects14 beyond its contribution as an 
energy source for colonocytes.15 Thus, although butyrate sup-
plementation has been proposed as a therapeutic approach in 
IBD,16–19 whether it could have any beneficial effects remains an 
open question.
Here, we take advantage of the access to human primary 
epithelial organoid cultures to test the effects of butyrate on 
healthy and IBD-affected intestinal epithelium. Using this ex 
vivo model, we also assess the impact of inflammation on the 
epithelial response to this bacterial metabolite.
METHODS
More detailed information is provided in Supplementary 
Methods, available online.
Patient Population
Patients with an established diagnosis of UC or CD of at 
least 3  months’ duration and non-IBD controls (Ctrl) were in-
cluded in the study after obtaining written informed consent. 
Non-IBD controls were those subjects undergoing surgery for 
colorectal cancer (CRC), colonoscopy for mild gastrointes-
tinal symptoms, or screening for CRC (none of these controls 
presented colonic lesions). Colonic biopsy samples were collected 
during routine colonoscopies from non-IBD controls and patients 
with IBD with no evidence of colitis-associated dysplasia or ne-
oplasia, as assessed by chromoendoscopy. Biopsy samples from 
patients with IBD were collected from previously involved or 
mildly inflamed sigmoid mucosa. Surgical samples from patients 
with IBD were obtained after colectomies were performed for 
refractoriness to medical treatment. For samples from non-IBD 
controls who were undergoing surgery, a segment of healthy mu-
cosa was collected at least 10 cm from the margin of the affected 
area. Supplementary Table 1 shows the clinical and demographic 
characteristics of the subjects included in the study. Samples 
were distributed among different subgroups on the basis of the 
experimental approaches used. Patients were recruited at the 
Department of Gastroenterology, Hospital Clinic Barcelona, and 
Hospital Mútua de Terrassa. The study protocol was approved by 
the ethics committees of both centers.
Assessment of Disease Activity
Endoscopic UC activity at the time of  the colonos-
copy was categorized according to the Mayo endoscopic 
subscore.20 Active UC was defined as a Mayo endoscopic 
subscore of  ≥1, quiescent UC as a Mayo score of  0 in a 
previously involved segment. In CD patients, the Simple 
Endoscopic Score for Crohn’s Disease (SES-CD) was 
used21 for each segment. Active CD was defined as an 
SES-CD of  ≥3, quiescent CD as an SES-CD score of  ≤2 in 
a previously involved segment. For fecal samples (Group 5) 
(Supplementary Table 1), disease activity was defined using 
the Crohn’s Disease Activity Index (CDAI) as there was no 
endoscopic information available.
Fecal Butyryl CoA:Acetate CoA-Transferase 
Quantification
Feces from Ctrl and CD patients (Group  5) 
(Supplementary Table 1) were collected in Stool DNA Stabilizer 
(Stratec, Germany) and processed with the PSP Spin Stool 
DNA Kit (Stratec) following the manufacturer’s instructions. 
To amplify the bacterial butyryl CoA:acetate CoA-transferase 
(BCoAT) gene, previously designed primers were used (Sigma, 
Saint Louis, MO, USA).22 The ribosomal 16S gene was used 
as an internal control. Syber Green–based chemistry (Applied 
Biosystems) was used following the manufacturer’s instructions. 
Fluorescence was detected by the ABI PRISM 7500 Fast 
RT-PCR System (Applied Biosystems).
Epithelial Organoid Culture
Biopsy or surgical specimens from non-IBD controls 
and patients with IBD were used for generating epithelial 
organoid cultures (EpOCs). Crypts embedded in Matrigel (BD 
Biosciences, San Jose, CA, USA) were cultured and passaged 
as previously described.23 Medium used for EpOC expansion 
contained Wnt3a-conditioned medium (produced using an 
L-Wnt3a cell line, ATCC CRL-2647) and Advanced DMEM/
F12 medium (Invitrogen, Carlsbad, CA, USA) 50:50, 2 mM of 
Glutamax, 10 mM of HEPES, N-2 (1×; Gibco, Grand Island, 
NY, USA), B-27 without retinoic acid (1×; Gibco), 10 mM of 
nicotinamide (Sigma), 1 mM of N-Acetyl-L cysteine (Sigma), 
500 ng/mL of R-spondin-1 (RSPO1, Sino Biologicals, Beijing, 
China), 50  ng/mL of human epidermal growth factor (EGF; 
Invitrogen), 100 ng/mL of human Noggin (Peprotech, Rocky 
Hill, NJ, USA), 1 μg/mL of Gastrin (Tocris Bioscience, Bristol, 
UK), 500  nM of LY2157299 (Axon MedChem, Groningen, 
the Netherlands), 10 μM of SB202190 (Sigma), and 0.01 μM 
of prostaglandin E2 (PGE2; Sigma). To induce EpOC differ-
entiation into differentiated EpOCs (d-EpOCs), nicotinamide, 
SB202190, and Wnt3a-conditioned medium were removed 
from the culture medium. RSPO1 was reduced to 250 ng/mL 
during the first 4  days and then completely removed. To test 
the effect of butyrate on organoids, EpOCs and d-EpOCs 
were stimulated with 0.5 or 5 mM of sodium butyrate (Sigma). 
Incubation of d-EpOCs with 0–50  ng/mL of tumor necrosis 
factor alpha (TNFα; Gibco) was performed for 20 hours when 
indicated.
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RNA Isolation
Total RNA from first-passage EpOCs and from biopsy 
samples (Group  1–3) (Supplementary Table 1) previously 
placed in RNAlater RNA Stabilization Reagent (Qiagen, 
Hilden, Germany) was isolated using the RNeasy Kit (Qiagen).
Microarray Analysis
For microarray analysis, paired first-passage EpOCs 
and d-EpOCs generated from colonic samples of non-IBD 
controls, incubated with butyrate as indicated, were used. 
The derived cRNA was hybridized to high-density oligonu-
cleotide Affymetrix GeneChip Human Genome U219 Array 
(Affymetrix, Santa Clara, CA, USA). Raw data were analyzed 
using Bioconductor tools in R (V.3.1.0). Microarray raw data 
(CEL files) and processed data have been deposited in NCBI’s 
Gene Expression Omnibus and are accessible through GEO 
Series accession No. GSE123553 ((https://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE123553; last accessed 12 June 
2019).
Quantitative Real-time Polymerase Chain 
Reaction 
Total RNA isolated from samples (Groups 1–3) 
(Supplementary Table 1) was transcribed to cDNA using the 
reverse transcriptase High Capacity cDNA Archive RT kit 
(Applied Biosystems, Carlsbad, CA, USA). Quantitative pol-
ymerase chain reaction (qPCR) was performed in the ABI 
PRISM 7500 Fast RT-PCR System (Applied Biosystems) using 
predesigned TaqMan Assays (Applied Biosystems).
Immunostaining
Immunohistochemical and immunofluorescent staining 
of tissue sections (Group  4) (Supplementary Table 1) was 
performed using commercially available antibodies: mouse anti-
EpCAM (1:100; Dako), rabbit anti-MCT1 (1:200, NovusBio), 
mouse anti-ABCG2 (1:50, Abcam), rabbit anti-ACADS (1:50, 
Abcam), and rabbit anti-GPR43 (1:50, LSBio). Image acquisi-
tion and overlay were performed on an Olympus BX51 micro-
scope (Tokyo, Japan) using CellF Software.
3H-Butyrate Beta-Oxidation Assay
To study the capacity of d-EpOCs to beta-oxidate bu-
tyrate, d-EpOCs were stimulated with 50  ng/mL of TNFα 
for 20 hours, and then with 5 mM of 3H-Butyrate (American 
Radiolabeled Chemicals, St. Louis, MO, USA) for an addi-
tional 24 hours. After incubation, 100 μL of supernatant was 
collected, and 900  μL of 0.6% phosphoric acid (Sigma) was 
added. The mixture was passed through a Bond Elut C18 
column (Agilent), previously conditioned with 1 mL of 100% 
methanol (VWR Chemical) and 1 mL of 0.6% phosphoric acid. 
The resultant elute with 3H-H2O from 3H-Butyrate oxidation 
was measured with HIDEX 300SL (Scintillation counter).
Statistical Analysis
Quantitative data are expressed as the mean and range, 
and categorical variables as absolute frequencies. A Wilcoxon 
test was performed to examine statistically different expression 
patterns between the 2 groups, and a Kruskal-Wallis test was 
performed to examine statistical significance in multiple group 
data sets, followed by a pairwise Wilcoxon test with Bonferroni-
Holm correction for multiple testing. A P value of <0.05 was 
considered statistically significant. Data were analyzed using R 
(version 3.1.0).
RESULTS
Low Content of Bacterial Butyryl CoA:Acetate 
CoA-Transferase in Crohn’s Disease Fecal 
Samples Does Not Result in Changes in Butyrate 
Concentration
To study the possible differences in butyrate produc-
tion by luminal bacteria in patients with CD, total SCFA 
concentrations were measured by HPLC in feces of active and 
inactive CD patients, as well as in non-IBD controls (Ctrl). 
In contrast to earlier studies,10–12 we observed no significant 
differences in fecal concentrations of SCFAs in CD patients, 
regardless of disease activity, compared with Ctrl (Fig. 1A).
BCoAT DNA expression in the same fecal samples was 
then measured as an indicator of the microbiota’s capacity to 
produce butyrate.8, 9, 24 We observed a significantly lower con-
tent of the BCoAT gene in the feces from active CD patients 
compared with Ctrl and CD patients in remission (Fig. 1B). 
Thus, we show a potentially reduced bacterial capacity to syn-
thesize butyrate in active CD patients that does not result in 
reduced fecal concentrations of this metabolite.
Butyrate Regulates the Transcriptional Profile of 
Healthy Human Intestinal Epithelial Organoids
We hypothesize that the discrepancy between the en-
zymatic capacity to produce butyrate and its concentration 
in feces could be explained by defects in the consumption of 
this metabolite in the context of inflammation. To test this 
hypothesis, first we established the effects of butyrate in the 
healthy epithelium using ex vivo human primary organoid 
cultures derived from Ctrl individuals. EpOCs were generated 
from colonic crypts and differentiated in vitro into d-EpOCs. 
Analysis of microarray gene expression data identified 2014 
genes differentially expressed (P ≤ 0.05; FDR ≤ 0.05) between 
EpOCs and d-EpOCs (Supplementary Fig. 1), which was in 
agreement with our previous results2 (GEO Series accession 
No. GSE75916; https://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=gse75916; last accessed 12 June 2019). The transcrip-
tional signatures of EpOCs and d-EpOCs stimulated with 
0.5 mM or 5 mM of butyrate for 1, 3, 6, and 24 hours were 
also analyzed. Principal component analysis (PCA) separated 
 Inflamm Bowel Dis • Volume 26, Number 1, January 2020
46
Ferrer-Picón et al
FIGURE 1. Feces from active CD patients present similar levels of fecal SCFAs and a decrease in fecal BCoAT content. A, Fecal SCFAs were measured 
by HPLC in Ctrl feces (n = 12) and feces from inactive (n = 11) and active (n = 10) CD patients. Values are expressed in µmol/g. B, The content of the 
fecal BCoAT gene was measured by qPCR in Ctrl feces (n = 12) and feces from inactive (n = 11) and active (n = 10) CD patients. BCoAT quantification 
was relative to the bacterial 16S ribosomal gene. Mean±SEMs. *P < 0.05; **P < 0.01 by 1-tailed Wilcoxon test.
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EpOC from d-EpOC populations (Supplementary Fig. 2). 
Butyrate induced a dose- and time-dependent transcriptional 
signature in both EpOCs and d-EpOCs, having a more pro-
found effect in the latter (Supplementary Table 2 and Fig. 2A). 
Indeed, >4000 genes (~50% of them upregulated) were signifi-
cantly modulated by 5 mM of butyrate at 24 hours on d-EpOCs 
(FDR ≤ 0.05; |FC| ≥ 1.5).
Ingenuity pathway analysis (IPA) of genes significantly 
regulated by 5 mM of butyrate at 24 hours revealed modula-
tion of mechanisms related to cell proliferation and survival, 
which were downregulated by butyrate in both organoid sys-
tems (Fig. 2B). In fact, butyrate significantly decreased the ex-
pression of proliferation markers (MYC and KI67) (Fig. 2C). 
In contrast, the regulation of pathways leading to cell death 
and necrosis was only confirmed in EpOCs (Fig. 2B), but 
not in d-EpOCs. More specifically, butyrate increased pro-
apoptotic AIFM3 and FOXO1 transcription and decreased the 
mRNA levels of the anti-apoptotic gene BCL2L2 in EpOCs 
(Fig. 2C). At 24 hours of butyrate stimulation, both EpOCs 
and d-EpOCs downregulated the expression of inflamma-
tory markers (CXCL1, HMGB1, and NFKB1), whereas they 
upregulated genes associated with the defense against oxidative 
stress (MT1X, CAT, and GPX3). HDAC3 mRNA levels also 
increased upon butyrate stimulation in both systems, in agree-
ment with histone deacetylase inhibition.25 In addition, butyrate 
increased ALDH1A3 transcriptional levels, 1 of the enzymes 
that participates in acid retinoic formation, a factor involved in 
the differentiation of gut-homing Treg cells26 and IgA-secreting 
B cells.27 Six of the genes most significantly regulated by 5 mM 
of butyrate in d-EpOCs at 24 hours and involved in the prolif-
eration and response to oxidative stress and immune functions 
were validated by real-time qPCR (Fig. 2D).
Given that d-EpOCs mimic the phenotype of 
differentiated epithelial cells residing on the luminal (upper) 
side of the crypt, which is directly exposed to bacteria and its 
metabolites, we decided to limit our study to the effects of bu-
tyrate on the d-EpOCs system.
Butyrate Response in IBD-Derived Differentiated 
Epithelial Organoids Is Comparable to That of 
Controls
Next, we asked if  epithelium derived from IBD patients 
responded differently to butyrate. We generated d-EpOCs from 
colonic biopsies of Ctrl and IBD patients with inactive disease. 
First, we analyzed a panel of genes associated with butyrate 
uptake and metabolism. We found no significant differences be-
tween Ctrl, UC, and CD organoids in the mRNA transcription 
of SLC16A1 and ABCG2, transporters, ACADS (an enzyme 
that participates in butyrate intracellular degradation), and 
the butyrate receptor GPR43 (Fig. 3A). Second, we examined 
the ability of d-EpOCs from Ctrl and IBD patients to con-
sume butyrate by measuring butyrate concentrations in culture 
supernatants after 24 hours of 5-mM butyrate supplemen-
tation. No differences were found in butyrate consumption, 
regardless of the origin of the sample (Fig. 3B). In addition, 
the modulation of butyrate-dependent genes (KI67, MT1X, 
and CXCL1) proved similar in Ctrl and UC- and CD-derived 
d-EpOCs (Fig. 3C). Overall, these data suggest that under 
steady-state conditions and in the absence of a concomitant 
pro-inflammatory stimulus, the intestinal epithelium from IBD 
patients presents the same intrinsic capacity to consume and 
respond to butyrate as that of Ctrl individuals.
The Inflamed Mucosa of IBD Patients Presents 
Alterations in Epithelial Butyrate Transport and 
Metabolism
Next, we asked whether active inflammation could affect 
butyrate consumption. To answer this question, we first meas-
ured the expression of the butyrate transporters SLC16A1 and 
ABCG2, along with the enzyme ACADS. All 3 transcripts were 
significantly reduced in colonic biopsies from active UC (AUC) 
and active CD (ACD) patients (Fig. 4A), in agreement with 
previous reports.28–32 Notably, MCT1 (encoded by SLC16A1), 
ABCG2, and ACADS proteins primarily localized in the apical 
epithelium of Ctrl mucosa but remained undetectable in the 
inflamed mucosa of both UC and CD patients (Fig. 4B). In con-
trast, expression of GPR43 was limited to a small fraction of 
cells within the epithelial layer and the lamina propria in healthy 
mucosa (Fig. 4B). Remarkably, both GPR43 mRNA and pro-
tein expression (predominantly within the lamina propria com-
partment) were increased in the inflamed IBD mucosa. GPR43+ 
cells may be newly recruited monocytes and neutrophils, which 
are known to express this butyrate receptor.33 Thus, active in-
flammation in both UC and CD patients is associated with sig-
nificant changes in the expression of those proteins involved in 
butyrate transport and metabolism.
TNFα Affects Butyrate Uptake and Response by 
the Intestinal Organoids
To mimic the effects of inflammation in the epithelium, 
d-EpOCs from healthy donors were stimulated with increasing 
doses of TNFα, a cytokine involved in the physiopathology of 
IBD. TNFα stimulation induced a significant dose-dependent 
decrease of SLC16A1 and ABCG2, as well an increase of 
GPR43 mRNA expression. Remarkably, TNFα had no effect 
on the transcription of ACADS (Fig. 5A). Next, we asked 
whether anti-TNF treatment could restore the expression of 
these genes. To this end, we examined the published findings 
on IBD patients with whole-transcriptome data available 
from biopsies before and after 8 weeks of infliximab induction 
therapy (series accession number GSE16879; https://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=gse16879; last accessed 
12 June 2019).34 Expression of SLC16A1 and ABCG2 was 
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FIGURE 2. Butyrate induces significant transcriptional changes in EpOCs and d-EpOCs. A, Heatmap representations of differentially expressed 
genes (FDR ≤ 0.05; |FC| ≥ 1.5) in EpOCs (n = 4 for each time and dose) and d-EpOCs (n = 4 for each time and dose) upon butyrate stimulation 
(0.5 mM and 5 mM). Differentially expressed genes in EpOCs and d-EpOCs are shown separately. Each row depicts 1 individual probe and each 
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significantly increased, whereas GPR43 transcripts were sig-
nificantly decreased after infliximab treatment (Supplementary 
Fig. 3), thus supporting a role for TNFα in the deregulation of 
these genes.
These data suggest that the changes observed in the ex-
pression of genes related to butyrate metabolism in inflamed 
IBD mucosa could be driven by increased levels of TNFα.
We subsequently determined the effects of TNFα on 
butyrate metabolism. First, levels of beta-hidroxybutyrate 
and acetoacetate, 2 ketone bodies produced upon butyrate 
consumption, were measured after sequential TNFα and bu-
tyrate stimulation. No differences were found in either meta-
bolic product after TNFα stimulation (Supplementary Fig. 
4). However, ketone body production possibly resulted from 
butyrate-independent cellular metabolism and may be affected 
by TNFα itself. Therefore, we measured butyrate consumption 
in the culture supernatants of d-EpOCs and found a signifi-
cant decrease in butyrate intake in cells previously exposed to 
TNFα (Fig. 5B). Moreover, direct beta-oxidation of butyrate 
was measured by the production of 3H-H2O following incuba-
tion with 3H-Butyrate. In agreement with the overall decrease 
in butyrate uptake, beta-oxidation of butyrate was significantly 
decreased after TNFα stimulation of d-EpOCs (Fig. 5C).
In addition, the expression of 2 enzymes involved in bu-
tyrate degradation (ACSM3 and ACADS) was measured after 
sequential TNFα and butyrate stimulation. TNFα alone did 
not regulate the transcription of either of the 2 genes (as seen 
for ACADS in Fig. 5A); however, both transcripts were signifi-
cantly upregulated by butyrate (Fig. 5D). This upregulation was 
significantly decreased by the previous exposure of d-EpOCS 
to TNFα.
Taken together, these results suggest that TNFα 
decreases butyrate consumption by the epithelium, potentially 
by deregulating the mechanisms of uptake and degradation.
We therefore sought to determine whether this decreased 
uptake of butyrate in TNFα-stimulated d-EpOCs could affect 
the transcriptional regulation of some of the main butyrate-
dependent genes identified above. In particular, we looked at 
genes involved in key epithelial pathways such as the response to 
oxidative stress (Fig. 6A), immune response and inflammasome 
(Fig. 6B and C, respectively), and structural and antimicrobial 
responses (Fig. 6D). Overall, TNFα stimulation did not mark-
edly alter the quality of the response of d-EpOCs to butyrate, 
although for some genes it did modulate the magnitude of the 
change (ie, it attenuated the butyrate-dependent upregulation 
of MTX1 (Fig. 6A) while further increasing the transcription 
of DEFB1, DEFB4B, and FN (Fig. 6D)).
Overall, we show that although TNFα does reduce the 
ability of the intestinal epithelium to uptake and metabolize 
butyrate, d-EpOCs continue to respond to SCFAs, which pro-
mote an antioxidative, antimicrobial, and overall protective ep-
ithelial response.
Ctrl- and CD-Derived Epithelium Respond 
Similarly to Fecal SCFAs Extracts
Although butyrate is 1 of  the most abundant SCFAs in 
the gut, the intestinal lumen contains other abundant SCFAs 
that may exert some potentially biological impact on IBD. To 
reproduce the effects of  this complex environment on the epi-
thelium, we obtained extracts of  SFCAs from the feces of  Ctrl 
and CD patients. SCFA concentrations from fecal extracts are 
detailed in Supplementary Table 3. SCFA fecal extracts from 
Ctrl feces (n  =  12) and feces from inactive (n  =  11) and ac-
tive (n = 11) CD or vehicle (organic solvent extract) patients 
were then used at a 1:50 dilution to stimulate Ctrl- (n  =  3) 
and CD-derived (n = 3) d-EpOCs. d-EpOCs stimulated with 
5 mM of butyrate were also included for comparison. Changes 
in expression were calculated for all stimulated conditions 
compared with vehicle-treated d-EpOCs (Fig. 7). The effects 
of  fecal extracts containing a complex mixture of  SCFAs were 
similar but overall less pronounced, compared with 5 mM of 
butyrate alone. Indeed, fecal extracts from Ctrl, inactive (I), 
or active (A) CD patients induced a significant decrease in 
the proliferation marker KI67 and an increase in MT1X and 
DEFB1 mRNA expression in both Ctrl and CD d-EpOCs 
(Fig. 7). Conversely, no or mild effects on IL18 and CXCL1 
expression were observed by incubation of  both Ctrl and CD 
d-EpOCs with SCFA extracts.
Overall, SCFAs containing fecal extracts from Ctrls and 
CD patients show qualitatively similar, though milder, effects 
when compared with 5  mM of butyrate on d-EpOCs. This 
could, at least in part, be due to the presence of lower SCFA 
concentrations in the extracts. Importantly, d-EpOCs from 
both Ctrl and CD patients show overall comparable behavior 
in response to SCFA fecal extracts. This further supports our 
initial observation that d-EpOCs from CD patients inherently 
respond to fecal metabolites.
column an experimental sample. High expression levels are shown in red and low expression levels in green. An unsupervised hierarchical cluster 
method, using a Euclidean distance and average linkage method, was applied for both gene and sample classification. B, Polar graph showing the 
top 15 pathways altered in EpOCs and d-EpOCs stimulated with 5 mM of butyrate compared with the control group after 24 hours, using IPA. The 
downregulated pathways (z-score ≤ 2) are shown in green, the upregulated pathways (z-score ≥ 2) in red. C, Venn diagram showing the number of 
genes differentially expressed in EpOCs and d-EpOCs stimulated with 5mM of butyrate compared with the control group after 24 hours. The overlap, 
in gray, shows the differentially expressed genes shared between the 2 data sets. A selection of up- and downregulated genes is shown. D, Technical 
validation of selected butyrate target genes. Relative mRNA levels by qPCR of selected genes were found to be differentially expressed in the mi-
croarray analysis in d-EpOCs stimulated with 5 mM of butyrate after 24 hours (n = 6). Messenger RNA levels are relative to ACTB mRNA expression. 
Mean±SEMs. *P < 0.05; **P < 0.01; ***P < 0.001 by 1-tailed Wilcoxon test.




In this study, we propose that the inflammation present in 
the intestinal mucosa of IBD patients can alter the capacity of 
the epithelium to metabolize and respond to butyrate. Indeed, 
based on BCoAT PCR analysis,22 our results show that although 
the abundance of butyrate-metabolizing bacteria was decreased 
in active CD stool samples, this did not correlate with a con-
comitant reduction of butyrate concentration or of any other 
analyzed SCFAs. Although earlier studies showed a significant 
decrease of fecal butyrate in IBD patients,10–12 most included 
small patient samples, did not properly stratify patients by di-
sease activity, or used a variety of analytical techniques, thus 
making any comparisons of the results challenging. The SCFA 
extracts prepared from the samples of our study also had sim-
ilar metabolite concentrations throughout groups and induced 
comparable responses in human epithelial organoid cultures ac-
cordingly. Nonetheless, measuring fecal SCFA content provides 
an incomplete measurement of the luminal metabolite content, 
as SCFAs are primarily consumed by the colonic epithelium 
and only around 5% of its production is estimated to be found 
in feces.35 Thus, large fluctuations in gut butyrate-producing 
bacteria may not necessarily result in dramatic changes in fecal 
butyrate concentrations. Regardless of the concentrations of 
luminal butyrate, we believe that the lack of any correlation 
between the abundance of butyrate-producing species and lu-
minal butyrate concentrations in IBD patients may reflect its 
impaired uptake and oxidation by inflamed colonic cells. This 
is in line with previous reports that suggest altered butyrate ox-
idative metabolism in UC patients.13 Moreover, a decrease in 
MCT1, the protein that acts as a transporter for butyrate and 
that is encoded by SLC16A1,28 along with expression of the 
enzymes involved in butyrate oxidation,36 are downregulated 
in IBD active mucosa. Both TNFɑ and interferon (IFN) ɣ 
have been shown to downregulate SLC16A1 expression in the 
human epithelial cell line HT-29 and to result in a decrease in 
butyrate uptake and oxidation,28 suggesting a potential role of 
FIGURE 3. Responses to butyrate of d-EpOCs derived from Ctrl and IBD patients are comparable. A, Relative mRNA expression by qPCR of SLC16A1, 
GPR43, ABCG2, and ACADS of Ctrl-derived (n = 10), UC-derived (n = 13), and CD-derived (n = 7) d-EpOCs. B, Butyrate consumption after 24 hours’ 
stimulation with 5 mM of butyrate in d-EpOCs derived from Ctrl and IBD patients. C, Relative mRNA expression by qPCR of previously described  
(Fig. 2) butyrate target genes in Ctrl-derived (n = 10), UC-derived (n = 13), and CD-derived (n = 7) d-EpOCs upon 5-mM butyrate stimulation during 
24 hours. Gene expression is relative to ACTB mRNA. Mean±SEMs. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by 1-tailed Wilcoxon test.
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FIGURE 4. Patients with active IBD present a deregulation in those genes associated with butyrate absorption, metabolism, and response. A, Relative 
mRNA expression of SLC16A1, GPR43, ABCG2, and ACADS by qPCR in colonic biopsies from non-IBD controls (n = 12), active UC (n = 10), and active CD 
(n = 10) patients. Messenger RNA levels are relative to ACTB expression. Mean±SEMs. *P < 0.05; **P < 0.01; ***P < 0.001 by pairwise Wilcoxon test with 
Bonferroni-Holm correction for multiple testing. B, Representative images and immunofluorescent immunohistochemical staining of tissue sections 
of colonic samples from Ctrl (n = 6) and active UC (n = 6) and CD (n = 7) patients. Protein expression was determined by immunofluorescent staining 
using a combination of MCT1 and GPR43 proteins (in green) with the epithelial marker EpCAM (in red). White arrows indicate GPR43-positive cells. 
Expression of ABCG2 and ACADS was detected by immunochemical staining. Images were taken with a ×20 objective lens and magnified with a ×40 
objective lens, except images of for MCT1, which were taken with a ×10 objective lens and magnified with a ×20 objective lens.
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inflammation in decreasing butyrate uptake and metabolism. 
However, the effects of inflammation on the other proteins in-
volved in butyrate consumption, specifically in the context of 
primary human cells, have not been previously reported.
Our study takes advantage of patient-derived organoid 
cultures to maintain human primary epithelium in culture, in 
lieu of immortalized cell lines. Human organoids have shown 
some similarities to cell lines in their response to butyrate (in-
hibition of proliferation, activation of reactive oxygen species 
detoxification pathways, enhanced epithelial barrier function, 
promotion of retinoic acid synthesis, and regulation of the 
inflammatory response),37–39 but also striking differences. For 
instance, HT-29 cells have been shown to produce TGFβ in re-
sponse to butyrate,40 whereas our whole-genome analysis shows 
no induction of TGFβ or TGFβ target genes when using pri-
mary epithelial organoids (data not shown), which indicates 
important differences between primary and immortalized cell 
systems. We also provide evidence that the intestinal stem and 
differentiated epithelium are highly sensitive to the presence of 
this bacterial metabolite, with both systems containing a large 
number of commonly regulated pathways. Remarkably, butyrate 
regulated genes that promote cell apoptosis in stem-enriched, 
but not differentiated, epithelial organoids. These results are in 
line with a previous study in mice that suggested that the po-
tential detrimental effects of high butyrate concentrations on 
the stem compartment are avoided by the crypt architecture.41
Ours is the first study to compare the intrinsic ability of 
human epithelial organoids from UC and CD patients to up-
take, metabolize, and respond to butyrate, along with the com-
plex SCFA mixtures extracted from fecal samples. We clearly 
show that organoids from noninflamed IBD mucosa respond 
to butyrate similarly to controls, which is consistent with recent 
observations by Vancamelbeke et al.,42 who found no differences 
in the response of control and UC cultures to butyrate, alone 
or in combination with TNFɑ/IFNγ. On the other hand, we 
confirmed in both ex vivo epithelial cultures and whole mucosal 
FIGURE 5. TNFα reduces butyrate consumption in d-EpOCs. A, Relative mRNA expression by qPCR of SLC16A1, GPR43, ABCG2, and ACADS in d-EpOCs 
(n = 8) upon TNFα stimulation at increasing doses for 24 hours. Gene expression is relative to the ACTB gene. B, Butyrate consumption after 24 
hours’ stimulation with 5 mM of butyrate in d-EpOCs stimulated with 50 ng/mL of TNFα. C, 3H-H2O production after 24 hours’ stimulation with 5 mM 
of 3H-Butyrate in the presence of TNFα. Values are represented as the fold-change (FC) with respect to the Ctrl. Mean±SEMs. *P < 0.05 by 1-tailed 
Wilcoxon test. D, Relative mRNA expression by qPCR of ACSM3 and ACADS in d-EpOCs upon TNFα and butyrate stimulation (n = 8). Gene expression 
is relative to the ACTB gene. Mean±SEMs. *P < 0.05; **P < 0.01 by 1-tailed Wilcoxon test.
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samples that the inflammatory milieu, in particular the presence 
of TNFɑ, does impact butyrate uptake and oxidation. Indeed, 
TNFɑ may be responsible for the downregulation of butyrate 
transporters in the human intestinal epithelium observed in pa-
tient biopsies, and that may result in decreased butyrate con-
sumption. In d-EpOCs, TNFɑ had no effect on the expression 
of ACADS or ACSM3, 2 enzymes involved in butyrate me-
tabolism that are instead upregulated by butyrate itself. Both 
transcripts, as shown here and elsewhere,13 are downregulated in 
active IBD biopsies, which could be explained by the decrease 
in butyrate uptake in the context of inflammation. In fact, using 
organoids, we also show that pretreatment with TNF decreases 
the butyrate-induced upregulation of both genes.
Overall our data confirm, using patient-derived organoids, 
the potent effects of butyrate on the intestinal epithelium and 
the impact that inflammation, at least in part mediated by the 
FIGURE 6. mRNA expression levels of selected butyrate and TNFα response genes. Relative mRNA expression by qPCR of genes associated with oxi-
dative stress (A), inflammation (B), inflammasome (C), and epithelial integrity and damage (D) in d-EpOCs stimulated with TNFα and butyrate (n = 8). 
Gene expression is relative to the ACTB gene. Mean±SEMs. *P < 0.05 by 1-tailed Wilcoxon test.
 Inflamm Bowel Dis • Volume 26, Number 1, January 2020
54
Ferrer-Picón et al
presence of TNFɑ, has on the ability of epithelial cells to up-
take, metabolize, and respond to this bacterial metabolite.
Moreover, we provide evidence that response to bu-
tyrate is not intrinsically altered in IBD patients under quies-
cent conditions, which thus supports the beneficial effects of 
butyrate in the absence of inflammation. Nonetheless, as the 
downregulation of butyrate transporters and enzymes is associ-
ated with both active UC and CD patients, supplementation of 
active patients with butyrate or SCFA extracts may not provide 
any beneficial effects as long as inflammation persists.
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